Approval · Notice of Compliance 36017 · 2022
OMVYENCE: Notice of Compliance 36017
Issued December 23, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36017
- Date
- December 23, 2022
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Administrative – Product Monograph Update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OMVYENCE | Not yet assigned | — |
Medicinal ingredients
- INFLIXIMAB 100 MG per VIAL